Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

RAD001 – Anti-Cancer Therapy, Anti-neoplastic agent by Novartis

The lungs and soft tissues are the most common secondary sites of renal cell cancer. Patients administered with Afinitor showed 67% progression-free survival compared to placebo.



  • Cross-section of a solid tumour
  • Renal cell carcinoma (RCC)
  • Common secondary sites of RCC

Go Top